# A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

> **NCT06333964** · PHASE3 · COMPLETED · sponsor: **Astrogen, Inc.** · enrollment: 169 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** AST-001
- **DRUG:** Placebo of AST-001

## Key facts

- **NCT ID:** NCT06333964
- **Lead sponsor:** Astrogen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-29
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333964, "A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06333964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*